Johnson & Johnson (JNJ)

Johnson & Johnson raised its 2025 sales outlook and dividend, while Q1 results topped expectations driven by strong cancer drug performance.

Johnson & Johnson stock fell alongside the broader market, despite beating first-quarter calls and hiking its sales outlook.

The company said the updated guidance includes costs estimated to be incurred as part of Trump’s tariffs on certain imports into the U.S.

Multinational healthcare company Johnson & Johnson (NYSE:JNJ) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 2.4% year on year to $21.89 billion. The company’s full-year revenue guidance of $92 billion at the midpoint came in 1.9% above analysts’ estimates. Its non-GAAP profit of $2.77 per share was 7.3% above analysts’ consensus estimates.

Johnson & Johnson's first-quarter results surpassed expectations with notable growth in sales and earnings.

U.S. stock futures were volatile on Tuesday following a two-day advance. Futures of major benchmark indices were mixed in premarket.

After two days of back-to-back gains in the spot market, U.S. stock futures had a choppy session Monday night as investors await several prominent companies' earnings reports this week.

Multinational healthcare company Johnson & Johnson (NYSE:JNJ) will be reporting results tomorrow before market open. Here’s what investors should know.

There are valid reasons for the market to remain focused on the tariffs issue since so much is happening in the broader economy.

Novartis commits $23 billion to expand U.S. manufacturing and R&D with 10 new facilities, aiming to produce all key U.S. medicines domestically and add thousands of jobs.

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

Here's why the 90-day tariffs delay doesn't help pharmaceutical companies.

Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety.

Investors are dumping growth stocks right now as new tariff policies rock the markets.

Three of the Dow's 30 components make for sensational buys amid a historic sell-off.

Goldman Sachs upgraded Johnson & Johnson (JNJ) from Neutral to Buy, citing underappreciated Innovative Medicine business and upcoming product cycles.

And we take a look at Texas Instruments and Taiwan Semiconductor.